Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals

Tania Hernáez-Alsina; Berta Caballol-Oliva; Álvaro Díaz-González; Cassia Guedes-Leal; María Reig

doi:10.1016/j.gastrohep.2019.05.003

Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals

Gastroenterol Hepatol. 2019 Oct;42(8):502-511. doi: 10.1016/j.gastrohep.2019.05.003. Epub 2019 Aug 28.

[Article in English, Spanish]

Authors

Tania Hernáez-Alsina¹, Berta Caballol-Oliva², Álvaro Díaz-González², Cassia Guedes-Leal², María Reig³

Affiliations

¹ Servicio de Aparato Digestivo, Hospital San Pedro, Logroño, La Rioja, España; Grupo BCLC, Unidad de Oncología Hepática, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Universidad de Barcelona, Barcelona, España.
² Grupo BCLC, Unidad de Oncología Hepática, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Universidad de Barcelona, Barcelona, España.
³ Grupo BCLC, Unidad de Oncología Hepática, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Universidad de Barcelona, Barcelona, España. Electronic address: MREIG1@clinic.ub.es.

PMID: 31472990
DOI: 10.1016/j.gastrohep.2019.05.003

Abstract

Eradication of the hepatitis C virus (HCV) with interferon-free therapies (DAAs) has modified the course of the disease, as the rate of patients with compensated cirrhosis who achieve a sustained virological response exceeds 95%. However, the impact on development of hepatocellular carcinoma (HCC) is currently in dispute. This argument could be divided into different key points: the impact of DAA on rate of HCC recurrence, the temporal link between starting DAAs and HCC recurrence, and finally, the aggressive pattern of HCC. Therefore, the aim of this review is to analyse the available results in this population of patients from a clinical perspective where the risks and benefits of HCV eradication with DAA therapies are evaluated in patients with complete response of HCC.

Keywords: AAD; Carcinoma hepatocelular; DAA; HCV; Hepatocellular carcinoma; Interferon-free; Libre interferón; Recurrence; Recurrencia; VHC.

Publication types

Review

MeSH terms

Antiviral Agents / administration & dosage
Antiviral Agents / adverse effects
Antiviral Agents / therapeutic use*
Carcinoma, Hepatocellular / etiology
Carcinoma, Hepatocellular / pathology*
Carcinoma, Hepatocellular / therapy
Carcinoma, Hepatocellular / virology
Disease Progression
Embolization, Therapeutic
Hepatectomy
Hepatitis C, Chronic / complications
Hepatitis C, Chronic / drug therapy*
Humans
Interferons
Liver Neoplasms / etiology
Liver Neoplasms / pathology*
Liver Neoplasms / therapy
Liver Neoplasms / virology
Neoplasm Recurrence, Local / epidemiology
Neoplasm Recurrence, Local / etiology*
Neoplasm Recurrence, Local / prevention & control
Prospective Studies
Retrospective Studies

Substances

Antiviral Agents
Interferons